Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis

Reuters Staff  |  

“Because of concerns about side effects, the European Medicines Agency did not approve tofacitinib for treatment of rheumatoid arthritis. The US Food and Drug Administration has approved the 5 mg dose for rheumatoid arthritis, but the package insert warns about serious infections and malignancy,” he adds.

Pfizer Inc. sponsored the trial, employed seven of the 15 authors, and had various relationships with five of the other authors.

ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Bachelez did not respond to a request for comments.

Related Articles

    Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

    Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    Herpes Zoster & Tofacitinib

    Shingles, also known as herpes zoster (HZ), is a common and sometimes debilitating disease that disproportionately affects elderly individuals and those who are immunocompromised. Patients with rheumatoid arthritis (RA) have a 1.5–2-fold higher risk of developing HZ compared with healthy adults. Treatment with some disease-modifying anti-rheumatic drugs (DMARDs) has been shown to increase this risk….